**Business Performance:** Anupam Rasayan delivered its highest-ever annual performance in FY26, with consolidated revenue reaching ₹2,383.6 Cr, a 65% YoY jump.

Consolidated Profit After Tax (PAT) grew significantly by 39% to ₹222.2 Cr.

For Q4FY26, consolidated revenue was ₹639.2 Cr (+26% YoY), though PAT saw an 11% de-growth to ₹56 Cr.

Agrochemicals contributed 55% of revenue, followed by Pharma (20%) and Performance Materials (18%). **Growth Drivers or Strategy:** The company is strategically focused on building a globally integrated specialty chemicals and CDMO platform, notably through the acquisition of Jayhawk Fine Chemicals in the US, enhancing its global footprint and market access.

A definitive agreement to acquire a controlling stake in Bliss GVS Pharma further strengthens its pharmaceutical value chain. **Recent Developments:** Anupam Rasayan successfully concluded the Jayhawk acquisition and signed the Bliss GVS Pharma agreement.

It also launched 3 new products and achieved its highest-ever operating cash flow of ₹334.3 Cr, reflecting improved operational efficiency. **Key Financial Metrics:** FY26 Consolidated Revenue: ₹2,383.6 Cr (+65% YoY), PAT: ₹222.2 Cr (+39% YoY). Q4FY26 Consolidated Revenue: ₹639.2 Cr (+26% YoY), PAT: ₹56 Cr (-11% YoY). FY26 EPS stood at ₹15.09. **Management Commentary / Outlook:** Management anticipates continued robust growth, driven by increasing contributions from the Performance Materials and Pharma segments, supported by a strong product pipeline and expanding global customer engagements.